Johnson Health Tech .Co Zukünftiges Wachstum
Future Kriterienprüfungen 4/6
Johnson Health Tech .Co wird ein jährliches Gewinn- und Umsatzwachstum von 33.4% bzw. 12.4% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 33.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 24.5% betragen.
Wichtige Informationen
33.4%
Wachstumsrate der Gewinne
33.4%
EPS-Wachstumsrate
| Leisure Gewinnwachstum | 22.6% |
| Wachstumsrate der Einnahmen | 12.4% |
| Zukünftige Eigenkapitalrendite | 24.5% |
| Analystenabdeckung | Low |
| Zuletzt aktualisiert | 25 Sep 2024 |
Jüngste Aktualisierungen zum künftigen Wachstum
Recent updates
Does Johnson Health Tech .Co (TWSE:1736) Deserve A Spot On Your Watchlist?
Nov 26
Johnson Health Tech .Co's (TWSE:1736) Returns On Capital Are Heading Higher
Oct 16Johnson Health Tech .Co., Ltd.'s (TWSE:1736) 28% Jump Shows Its Popularity With Investors
Sep 30News Flash: Analysts Just Made A Meaningful Upgrade To Their Johnson Health Tech .Co., Ltd. (TWSE:1736) Forecasts
Sep 26Are Johnson Health Tech .Co., Ltd. (TWSE:1736) Investors Paying Above The Intrinsic Value?
Sep 23Is Johnson Health Tech .Co (TWSE:1736) A Risky Investment?
Sep 05Johnson Health Tech .Co., Ltd.'s (TWSE:1736) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Jul 16Investors Appear Satisfied With Johnson Health Tech .Co., Ltd.'s (TWSE:1736) Prospects As Shares Rocket 32%
May 08Does Johnson Health Tech .Co (TWSE:1736) Have A Healthy Balance Sheet?
Apr 09The Strong Earnings Posted By Johnson Health Tech .Co (TWSE:1736) Are A Good Indication Of The Strength Of The Business
Mar 23Johnson Health Tech .Co (TWSE:1736) Shareholders Will Want The ROCE Trajectory To Continue
Mar 06These 4 Measures Indicate That Johnson Health Tech (TPE:1736) Is Using Debt Extensively
Apr 26Investors Met With Slowing Returns on Capital At Johnson Health Tech (TPE:1736)
Mar 27Did You Miss Johnson Health Tech's (TPE:1736) Impressive 180% Share Price Gain?
Feb 25Should Johnson Health Tech. Co., Ltd. (TPE:1736) Focus On Improving This Fundamental Metric?
Feb 10These 4 Measures Indicate That Johnson Health Tech (TPE:1736) Is Using Debt Reasonably Well
Jan 26
Do Institutions Own Johnson Health Tech. Co., Ltd. (TPE:1736) Shares?
Jan 11Returns On Capital At Johnson Health Tech (TPE:1736) Paint An Interesting Picture
Dec 27The Johnson Health Tech (TPE:1736) Share Price Has Gained 144%, So Why Not Pay It Some Attention?
Nov 27Gewinn- und Umsatzwachstumsprognosen
| Datum | Umsatz | Gewinne | Freier Cashflow | Bargeld aus operativen Tätigkeiten | Durchschn. Anz. Analysten |
|---|---|---|---|---|---|
| 12/31/2026 | 57,994 | 3,206 | 4,043 | 4,956 | 1 |
| 12/31/2025 | 53,281 | 2,856 | 2,261 | 3,166 | 1 |
| 12/31/2024 | 47,272 | 2,051 | 1,156 | 2,090 | 1 |
| 9/30/2024 | 43,131 | 1,283 | 1,276 | 2,076 | N/A |
| 6/30/2024 | 40,732 | 1,177 | 3,164 | 3,932 | N/A |
| 3/31/2024 | 39,060 | 1,219 | 4,117 | 4,948 | N/A |
| 12/31/2023 | 38,070 | 710 | 3,135 | 3,843 | N/A |
| 9/30/2023 | 36,838 | 590 | 1,989 | 2,404 | N/A |
| 6/30/2023 | 35,191 | 444 | 28 | 465 | N/A |
| 3/31/2023 | 33,122 | -300 | -632 | -291 | N/A |
| 12/31/2022 | 33,613 | 429 | -48 | 392 | N/A |
| 9/30/2022 | 31,863 | 369 | -1,071 | -238 | N/A |
| 6/30/2022 | 31,052 | -361 | -1,469 | -651 | N/A |
| 3/31/2022 | 31,036 | 53 | -3,659 | -2,818 | N/A |
| 12/31/2021 | 30,779 | 38 | -4,295 | -3,537 | N/A |
| 9/30/2021 | 30,765 | 53 | -3,341 | -2,681 | N/A |
| 6/30/2021 | 31,024 | 1,011 | -1,542 | -798 | N/A |
| 3/31/2021 | 30,102 | 999 | 1,279 | 2,005 | N/A |
| 12/31/2020 | 28,367 | 679 | 2,107 | 2,942 | N/A |
| 9/30/2020 | 26,901 | 894 | 1,818 | 2,563 | N/A |
| 6/30/2020 | 25,584 | 784 | 1,680 | 2,409 | N/A |
| 3/31/2020 | 25,570 | 1,015 | 176 | 990 | N/A |
| 12/31/2019 | 25,373 | 1,293 | 234 | 943 | N/A |
| 9/30/2019 | 24,460 | 1,129 | 74 | 695 | N/A |
| 6/30/2019 | 23,708 | 979 | -56 | 591 | N/A |
| 3/31/2019 | 22,609 | 612 | 743 | 1,337 | N/A |
| 12/31/2018 | 21,757 | 390 | 348 | 981 | N/A |
| 9/30/2018 | 20,769 | 189 | 131 | 956 | N/A |
| 6/30/2018 | 20,009 | 67 | N/A | 954 | N/A |
| 3/31/2018 | 19,540 | -6 | N/A | 13 | N/A |
| 12/31/2017 | 19,494 | 130 | N/A | -74 | N/A |
| 9/30/2017 | 19,477 | 358 | N/A | -939 | N/A |
| 6/30/2017 | 19,958 | 453 | N/A | -215 | N/A |
| 3/31/2017 | 20,191 | 716 | N/A | 818 | N/A |
| 12/31/2016 | 20,165 | 716 | N/A | 1,258 | N/A |
| 9/30/2016 | 19,659 | 710 | N/A | 2,014 | N/A |
| 6/30/2016 | 18,764 | 769 | N/A | 282 | N/A |
| 3/31/2016 | 17,963 | 563 | N/A | -154 | N/A |
| 12/31/2015 | 16,975 | 564 | N/A | -217 | N/A |
| 9/30/2015 | 16,520 | 1,940 | N/A | -813 | N/A |
| 6/30/2015 | 16,345 | 1,976 | N/A | 703 | N/A |
| 3/31/2015 | 16,313 | 2,296 | N/A | 2,482 | N/A |
| 12/31/2014 | 16,551 | 2,638 | N/A | 1,851 | N/A |
| 9/30/2014 | 16,262 | 1,477 | N/A | 2,232 | N/A |
| 6/30/2014 | 15,939 | 1,366 | N/A | 1,642 | N/A |
| 3/31/2014 | 15,416 | 1,058 | N/A | 398 | N/A |
| 12/31/2013 | 15,071 | 857 | N/A | 773 | N/A |
Analystenprognosen zum zukünftigen Wachstum
Einkommen vs. Sparrate: 1736Das prognostizierte Gewinnwachstum (33.4% pro Jahr) liegt über der Sparquote (1.1%).
Ertrag vs. Markt: 1736Die Erträge des Unternehmens (33.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt TW (19.5% pro Jahr).
Hohe Wachstumserträge: 1736Es wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.
Einnahmen vs. Markt: 1736Die Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als der Markt TW (12.6% pro Jahr).
Hohe Wachstumseinnahmen: 1736Die Einnahmen des Unternehmens (12.4% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.
Wachstumsprognosen für den Gewinn je Aktie
Künftige Eigenkapitalrendite
Künftige Eigenkapitalrendite: 1736Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich hoch sein (24.5%)